Drug Profile
Methylsamidorphan
Alternative Names: ALKS-37; RDC-1036Latest Information Update: 22 Aug 2012
Price :
$50
*
At a glance
- Originator Rensselaer Polytechnic Institute
- Developer Alkermes plc
- Class Amides; Morphine derivatives; Small molecules
- Mechanism of Action Opioid receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Constipation
Most Recent Events
- 30 Jun 2012 Alkermes completes a phase IIb trial for Opioid-induced constipation in USA (NCT01418092)
- 30 May 2012 Discontinued - Phase-II for Opioid-induced constipation in USA (PO)
- 13 Mar 2012 Alkermes completes enrolment in its phase IIb trials for Opioid-induced constipation in USA (NCT01382797; NCT01418092)